Table of Contents
What changed
Operating revenue grew 13.9% to NZ$10.7m, driven by higher royalty income on system sales recovering from COVID-affected comparatives. Profit before tax rose 41.5% to NZ$0.7m and NPAT rose 36.5% to NZ$0.6m, with the gap between the two explained by the effective tax rate moving to 26.0% from 23.3%. Operating cash flow was NZ$1.3m and capex NZ$0.5m, leaving pre-lease free cash flow of NZ$0.8m. The group remained debt-free with cash of NZ$7.4m against total equity of NZ$11.5m, and receivable days improved to ~31 from ~35.
What matters
- PBT is the cleaner operating read. PBT growth of 41.5% is materially stronger than NPAT growth of 36.5% purely because of a higher effective tax rate; there are no disclosed discontinued operations or one-offs driving the gap. The underlying operating trajectory is better than the bottom line suggests.
- Geographic concentration is extreme. New Zealand contributes ~99.6% of segment revenue and generated a ~NZ$1.1m segment result, while International (~0.4% of revenue) lost NZ$0.3m. Group earnings are effectively a single-country story, and any international reinvestment is a drag rather than a growth contributor at current scale.
- Cash generation is real but modest in absolute terms. Pre-lease FCF of NZ$0.8m equates to ~139% of NPAT, and the balance sheet carries no debt. However, FCF/NPAT fell from ~190% in the prior comparable period, so cash conversion strengthened the quality case less than it did last year.
Expectations
No stated targets or forward-work disclosures accompany this release, so run-rate assessment is limited. The FY22 shape is informative: HY22 delivered 55.7% of full-year revenue, 63.0% of EBITDA, and 95.9% of full-year NPAT, implying an H2 NPAT contribution of only ~NZ$0.02m. If that first-half-weighted pattern repeats, the strong HY23 print should not be straight-line annualised. Annualising HY23 revenue gives ~NZ$21.5m, roughly 11.7% above FY22's NZ$19.3m, which is directionally consistent with the 13.9% revenue growth but says nothing about whether H2 margin compression recurs.
Quality of result
The result looks durable at the revenue and PBT level: growth is attributed to higher royalty income on recovering system sales rather than working-capital release or one-offs, and receivable days improved rather than stretched. EBITDA-to-OCF conversion of ~76% is consistent with the prior comparable and not flagged as deteriorating. The main quality caveats are (i) comparison is against a COVID-depressed base that the company itself estimates cost ~NZ$5.9m of system sales in FY22, (ii) the International segment continues to consume profit generated in NZ, and (iii) no gross margin or cost-of-sales data is disclosed, so margin durability cannot be independently tested.
Unresolved
- Does the FY22 pattern of near-zero H2 NPAT repeat in H2 FY23, and if so what is driving the seasonal margin collapse?
- What is the plan and timeline for the International segment to stop consuming ~NZ$0.3m per half, and is further investment planned?
- How much of the 13.9% revenue lift is cyclical COVID recovery versus underlying system growth, given the company's own NZ$5.9m COVID impact estimate?
- No dividend, NTA per share, or forward-work disclosures were provided, so payout sustainability and valuation anchors cannot be assessed.
This briefing cannot assess post-balance-date trading, management commentary beyond the supplied excerpts, or any guidance for the remainder of FY23.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $10727.5m | $10727.5m | flat |
| EBITDA | $1638.6m | $1638.6m | flat |
| Net profit after tax | $552.3m | $552.3m | flat |
| Net cash inflow from operating activities | $1253.2m | $1253.2m | flat |
| Total assets | $40139.2m | $40139.2m | flat |
Reference: annolyse.ai/briefings/bfg-hy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| New Zealand | $11296.2m | $11296.2m | $1096.4m | +0.0pp |
| International | $39.6m | $39.6m | −$349.8m | +0.0pp |
Reference: annolyse.ai/briefings/bfg-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| PBT growth | +41.5% | — | cleaner earnings measure |
| Effective tax rate | 26.0% | 23.3% | — |
| OCF / EBITDA (cash conversion) | 76.5% | 76.5% | stable |
| FCF pre-lease | $768.8m | $768.8m | +$0.0m |
| FCF / NPAT | 139.2% | 190.0% | complementary conversion metric |
| Capex % revenue | 4.5% | 5.1% | — |
| Capex | −$484.4m | $484.4m | −$968.9m |
| Debtor days | 30.7 | 35.0 | -4.3 days |
| Operating working capital | $2526.3m | $2526.3m | +$0.0m absorbed |
| Trade debtors | $1815.6m | $1815.6m | +$0.0m |
| ROE (annualised) | 4.8% | 3.5% | Strengthening |
| HY22 share of FY22 revenue | 55.7% | — | Other half was 44.3% |
| HY22 share of FY22 EBITDA | 63.0% | — | Other half was 37.0% |
| HY22 share of FY22 NPAT | 95.9% | — | Other half was 4.1% |
| Profit from continuing operations | $552.3m | — | — |
Reference: annolyse.ai/briefings/bfg-hy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.